retatrutide type 2 diabetes trial results Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide TRANSCEND-T2D-1 topline results are

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial

Referral to endocrinology, cardiology, or lipid specialists may be warranted for complex cases involving multiple cardiovascular risk factors, familial hypercholesterolemia, severe hypertriglyceridemia (500 mg/dL), or inadequate response to initial therapy

A new oral GLP-1 therapy, orforglipron (Foundayo) by Eli Lilly and Company, has received US FDA approval, marking a major step forward in accessible weight-management solutions and intensifying competition with Novo Nordisk

protein-rich foods like eggs, meat, and tofu

Individuals who stopped using GLP-1RAs were categorized into interruption and discontinuation groups

COAs are available upon request for applicable batches